The lending market for WTO has effectively locked up. Cost to borrow exploded to 391% on May 1 — up 235% in a single week — while availability has tightened to near-zero as the micro-cap electronics manufacturer shed a third of its value in five trading days.
The numbers here are stark. Short interest jumped 164% in a single day, rising to 2.54% of free float on May 1. That followed a week where overall short positioning grew nearly 150%.
The cost to borrow tells the same story. At 391%, borrowing WTO stock now costs roughly four times the value of the position per year in financing charges alone. That compares to 75% just two days prior, on April 30.
Availability has collapsed in lockstep. With utilization sitting at 97.74% — just shy of the 52-week high of 100% hit multiple times in recent weeks — almost every share in the lending pool is already lent out. There is virtually no room left for new short positions to be established without forcing existing borrowers to compete for the same scarce supply.
The trigger is clear. WTO has fallen 34% over the past week and 45% over the past month. Short sellers have been pressing the position aggressively into that decline.
The stock closed at $1.50 on May 1. At that level, WTO is a micro-cap with minimal institutional support — just three reported holders on record as of end-2025, led by UBS Asset Management with 7,220 shares.
The ORTEX short score stands at 61.3. The utilization rank sits in the 4th percentile, meaning virtually no other stock in the universe has a tighter borrow market.
The cost-to-borrow level at 391% is self-limiting. At this rate, sustaining a short position becomes extremely expensive. Any catalyst that forces short sellers to cover — a price reversal, a halt, or a borrow recall — could move fast in a pool this thin. The next earnings event is scheduled for August 7.
Data summary
See the live data behind this article on ORTEX.
Open WTO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
